StandardX raises £10M Seed to build an accelerator-based isotope refinery for cancer medicine and fusion

StandardX (London) has raised £10 million (approximately €11.8 million) in a Seed round co-led by Vsquared Ventures and East X Ventures, with firstminute capital, UKI2S (the UK Innovation and Science Seed Fund), Brevan Howard Macro Venture, and Geometry participating. Founded in 2025 by nuclear engineers Richard Pearson (CEO) and Ross Allen (CTO), the company is building an accelerator-based isotope refinery to produce rare isotopes at commercial scale for cancer treatment and fusion energy.

The problem is structural. Rare isotopes — short-lived radioactive elements — are essential to modern oncology. Technetium-99m, used in millions of diagnostic scans each year, is produced as a byproduct of uranium fission in ageing research reactors, most of them operating beyond their designed lifespan. Targeted alpha therapies (TATs) — a class of cancer treatment using short-lived, high-energy emitters such as actinium-225 and bismuth-213 — are showing strong clinical results but face supply bottlenecks severe enough to throttle trial enrolment. Tritium, needed for commercial fusion reactors, faces a parallel constraint.

A different production model

StandardX is betting on particle accelerators as a route around the reactor problem. Cyclotrons and linacs can be licensed under industrial rather than nuclear regulations, sited in urban industrial zones, and scaled incrementally by adding units — without the 15-20 year lead time of a new research reactor. The company calls its planned facility an "accelerator-based isotope refinery," a framing that emphasises production engineering over research and signals ambitions closer to a semiconductor fab than a national laboratory.

Pearson is direct about the demand side: "Shortages are most acute in cancer medicine, already impacting patients today, and stalling progress in the development of next-generation treatments. This problem will only get worse, with new cancer cases projected to increase 67% by 2050."

The 2027 test

The roadmap is concrete: secure a first industrial site in London, advance design and construction of the refinery, and pilot isotope production with a named medical partner in 2027. Industrial-scale production is targeted from 2029.

UKI2S's participation lends credibility to the regulatory path — the UK government's innovation seed fund does not typically back companies whose licensing strategy is speculative. Brevan Howard Macro Venture's presence suggests conviction at a different level: that the global isotope supply-demand imbalance is structural, and that an infrastructure company positioned to resolve it carries genuine macro upside. The 18-month test is whether the 2027 pilot delivers pharmaceutical-grade purity and specific activity at a production cost per dose that oncology programmes can pay.